Kiran Mazumdar-Shaw, Biocon’s founder and chairperson, has reportedly put in place a structured succession plan for the biotechnology firm, identifying her niece, Claire Mazumdar, as the future leader.Having built Biocon over more than four decades and without a direct heir, Mazumdar-Shaw told Fortune India in an interview that she believes Claire Mazumdar is well-suited to guide the company’s next phase, which is expected to be shaped by advancements in biotechnology and artificial intelligence. “I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” Mazumdar-Shaw said in the interview.

“I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company.”

Who is Claire Mazumdar?

Claire Mazumdar, 37 years of age, currently heads Bicara Therapeutics as its founder and CEO. The firm, which was incubated by Biocon and later listed on NASDAQ, went public in 2024 and now has a market valuation of over $1.6 billion. She has an academic background that includes degrees from Massachusetts Institute of Technology and Stanford University, along with a PhD in cancer biology, and has previously worked with Third Rock Ventures and Rheos Medicines.

Mazumdar-Shaw also referred to a broader support network within the family that could contribute to Biocon’s future direction, including Claire’s brother, Eric Mazumdar, a professor at California Institute of Technology, and her husband, Thomas Roberts, who is associated with Massachusetts General Hospital.Alongside succession planning, the company has undertaken a broader restructuring. It has combined its generics and biologics divisions, worked on reducing its debt burden, and streamlined its overall structure.

A major focus remains on biosimilars, which contribute roughly 60% of revenue, with 12 products already commercialised and around 20 more under development.Leadership changes are also in progress across group entities. Shreehas Tambe has assumed the role of CEO and managing director at Biocon Biologics, while Siddharth Mittal is set to take charge of Syngene International from July 1.Looking ahead, Mazumdar-Shaw indicated that Biocon’s growth strategy will centre on differentiated biosimilars, the development of original biologic therapies, and a stronger integration of artificial intelligence into its research and development capabilities.